More people with prostate cancer, the second most common type of cancer in men globally, will soon be able to receive treatment with Nubeqa (darolutamide).
The US Food and Drug Administration has approved a supplemental application for the oral androgen receptor blocker, for use in people with metastatic hormone-sensitive prostate cancer.
The nod is based on results from the Phase III ARASENS trial, which show Nubeqa reduced the risk of death by 32.5% when paired with androgen deprivation therapy (ADT) and docetaxel.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze